Ensysce Biosciences, INC 8-K filings

Ensysce Biosciences announced its first quarter 2024 financial results and provided updates on its clinical programs, including the planned Phase 3 trial for PF614 and Breakthrough Therapy designation for PF614-MPAR.

Ensysce Biosciences believes it has met Nasdaq's minimum stockholders' equity requirement of $2.5 million following recent warrant exercises.

Ensysce Biosciences has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, adding to existing concerns about the company's compliance with listing requirements.

Ensysce Biosciences announced its financial results for the fourth quarter and full year 2023, highlighting progress in clinical programs and a Breakthrough Therapy designation for PF614-MPAR.

Ensysce Biosciences has successfully raised approximately $4.7 million by inducing warrant holders to exercise existing warrants at a reduced price, while also issuing new warrants.